Quote this publication Share Print

VOTUBIA

-
Opinions on drugs - Posted on Jul 03 2013

Reason for request

Extension of the indication

-


Clinical Benefit

Substantial

Substantial AB


Clinical Added Value

moderate

Given the efficacy of VOTUBIA (everolimus) in reducing renal angiomyolipoma volume associated with tuberous sclerosis complex in adult patients, VOTUBIA provides a substantial improvement in actual benefit (IAB III) in the treatment of patients not requiring immediate surgery (nephrectomy or embolisation).


Contact Us

Évaluation des médicaments

See also